Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study-Reference-Cited by-同舟云学术

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

Published:2010-01 Issue:3 Volume:28 Page:849-857
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Leroux-Roels Isabel,Roman François,Forgus Sheron,Maes Cathy,De Boever Fien,Dramé Mamadou,Gillard Paul,van der Most Robbert,Van Mechelen Marcelle,Hanon Emmanuel,Leroux-Roels Geert

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference29 articles.

1. World Health Organization (WHO). Global Alert and Response. Pandemic (H1N1) 2009. World Health Organization, http://www.who.int/csr/disease/swineflu/en/index.html; 2009 [accessed 27.09.09].

2. WHO. Global Alert and Response. Avian influenza. World Health Organization, http://www.who.int/csr/disease/avian_influenza/en/index.html; 2009 [accessed 27.09.09].

3. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). European Agency for the Evaluation of Medicinal Products; April 5, 2004.

4. European Committee for Proprietary Medicinal Products. Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006). European Agency for the Evaluation of Medicinal Products; January 24, 2007.

5. Food and Drug Administration (FDA) Guidance for Industry. Clinical data needed to support the licensure of pandemic influenza vaccines. US Food and Drug Administration, http://www.fda.gov/cber/gdlns/panfluvac.htm; 2007 [accessed 27.09.09].

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Downregulation of hypocretin/orexin after H1N1 Pandemrix vaccination of adolescent mice;SLEEP;2024-01-16

2. Comparative Immunogenicity of the Gam-COVID-Vac Vaccine under Intranasal and Intramuscular Administration;Journal Biomed;2023-12-04

3. Baseline immune states (BIS) associated with vaccine responsiveness and factors that shape the BIS;Seminars in Immunology;2023-11

4. New-age vaccine adjuvants, their development, and future perspective;Frontiers in Immunology;2023-02-24

5. Inactivated and Recombinant Influenza Vaccines;Plotkin's Vaccines;2023